By Pushkala Aripaka and Maggie Fick (Reuters) -AstraZeneca shares rose on Thursday after the drugmaker said it could face a ...

AstraZeneca could face a fine of up to $4.5 million in China over suspected unpaid taxes related to the import of two of its ...

European shares hovered near a record high on Thursday, buoyed by a raft of upbeat earnings, including drugmaker AstraZeneca, ...

AstraZeneca said on Thursday it has received a notice in China over unpaid taxes related to the import of two cancer ...

The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.

In an editorial, J. Mocco, MD, of Mount Sinai Health System in New York City, characterized the DISTAL and ESCAPE-MeVO ...

Drugmaker AstraZeneca has warned it could face a fine in China over possible unpaid import taxes, as it revealed strong sales ...

Astrazeneca's revenue jumped 21 per cent last year as the pharmaceutical recorded broad growth across its key businesses.

AstraZeneca Plc reported better-than-expected profit and sales in the fourth quarter and forecast further gains as the UK drugmaker’s blockbuster cancer drugs offset weakened China sales.

AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter 2024. The London-listed company ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

The AstraZeneca PLC ADR AZN advanced 2.86% to $70.94 Wednesday, on what proved to be an all-around favorable trading session ...